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Abstract
Next-generation genetic sequencing (NGS) technologies facilitate the screening of multiple genes linked to
neurodegenerative dementia, but there are few reports about their use in clinical practice. Which patients would most
profit from testing, and information on the likelihood of discovery of a causal variant in a clinical syndrome, are
conspicuously absent from the literature, mostly for a lack of large-scale studies. We applied a validated NGS dementia
panel to 3241 patients with dementia and healthy aged controls; 13,152 variants were classified by likelihood of
pathogenicity. We identified 354 deleterious variants (DV, 12.6% of patients); 39 were novel DVs. Age at clinical onset,
clinical syndrome and family history each strongly predict the likelihood of finding a DV, but healthcare setting and gender
did not. DVs were frequently found in genes not usually associated with the clinical syndrome. Patients recruited from
primary referral centres were compared with those seen at higher-level research centres and a national clinical neurogenetic
laboratory; rates of discovery were comparable, making selection bias unlikely and the results generalisable to clinical
practice. We estimated penetrance of DVs using large-scale online genomic population databases and found 71 with
evidence of reduced penetrance. Two DVs in the same patient were found more frequently than expected. These data should
provide a basis for more informed counselling and clinical decision making.
Introduction
In recent years we have seen an increasing focus on
research in dementia because of its rising prevalence in an
aging society [1]. Although most dementias appear
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sporadic, familial forms of early-onset dementia with
Mendelian inheritance (such as familial Alzheimer’s disease
(AD), familial frontotemporal dementia (FTD) or inherited
prion disease) have been crucial to furthering our under-
standing of the underlying clinical-pathological processes,
and the ensuing development of animal models and
experimental therapeutics [2]. Because of a series of high-
profile failures of advanced clinical trials, clinical research
has focussed on testing therapies earlier in disease using
imaging and cerebrospinal fluid (CSF) biomarkers to sup-
port a pre-dementia diagnosis [1]. Clinical genetic studies
offer the potential for presymptomatic diagnosis in at-risk
individuals with a high degree of confidence about mole-
cular pathology. Indeed, individuals carrying high-
penetrance mutations may be the most appropriate groups
in whom to test experimental therapeutics to prevent or
delay neurodegeneration—especially if those therapeutics
had been developed using animals expressing mutant
human proteins [3].
Several factors have historically inhibited clinicians from
considering a clinical genetic test in patients with dementia:
lack of information about the probability of finding a high-
penetrance mutation in single genes or the perception that
this is unlikely; genetic heterogeneity (multiple genes
causing the same pathology or clinical syndrome); high
costs; the length of time to return results; and the lack of
disease-modifying treatment options. These problems have
been exacerbated recently because of a high rate of gene
discovery and heterogeneity, particularly in FTD, with
many genes not becoming available for clinical testing [4].
Furthermore, recent discoveries show marked pleiotropy,
for example, the C9orf72 expansion mutation being found
in patients with clinically diagnosed FTD, amyotrophic
lateral sclerosis (ALS), Huntington’s disease-like syn-
dromes, and AD [5, 6]. The advent of next-generation
genetic sequencing (NGS)-based gene-panel technology
circumvents some of these problems by examining multiple
genes simultaneously; however, reports of the use of panel
diagnostics have been limited to small series that cannot
provide the statistical power needed to support firm genetic
evidence of pathogenicity of variants or clinical decision
making [7].
In this multi-site retrospective and prospective study, we
analysed a large series of samples from patients with het-
erogeneous dementia syndromes using a validated NGS
panel for dementia [7] and using gold-standard processes
and analytical strategies similar to those used by clinically
accredited laboratories. The 17-gene panel was combined
with amplification based assays of the C9orf72 and PRNP
expansion mutations, and exome sequencing in a large
subset: therefore, we assessed all the known common cau-
ses, and most of the rarer causes of genetic dementia syn-
dromes. We sought to establish statistically meaningful
prevalences of genetically determined dementias in referred
patients groups in order to provide data about predictive
factors in the clinical assessment, rates of mutation detec-
tion in relevant mutation categories, mutations in genes
unexpected for the phenotype, and multiple mutations in the
same individual (concurrent). These analyses were per-
formed on patient data classified by clinical diagnoses, not
neuropathology, reflecting the real-life situations and
uncertainty faced by clinicians. Using online large-scale
sequencing and data sharing projects we also sought to
clarify issues of causality and penetrance in the literature.
These data may help in interpretation of variants and in
formulating guidance about the clinical use of panel and
genomic technologies in dementia.
Methods
The study comprised 3241 samples: 2784 patient samples,
with clinical rather than pathological diagnoses to reflect
clinical reality at the point of care (1052 AD, 794 FTD, 299
prion disease, and 639 patients with a dementia syndrome
not consistent with other categories and associated with
motor symptoms (DemMot)), and 457 healthy elderly
control samples. From 1998 to 2015 the UCL Department
of Neurodegenerative Disease/MRC Prion Unit performed
research genetic testing with clinical feedback for PRNP,
PSEN1, PSEN2, APP, GRN and C9orf72. A total of 2352
UK patient samples were chosen retrospectively from these
referred cases. Selection was based on the documentation of
clinical parameters to be used in the predictive modelling
and to equalise sample numbers in the different diagnostic,
age, and family history categories and was blind to research
data about the presence of a gene variant. Four hundred and
thirty-two patient samples were referred prospectively for
the study: 165 patients from National Health Service (NHS)
cognitive disorders clinics in Southern England for gene-
panel testing research, and 267 patient samples from the
Division of Neurogenetics at the National Hospital for
Neurology and Neurosurgery (NHNN) for clinical gene-
panel testing. The study was approved by the local research
ethics committee.
Clinical syndrome was based on the assessment of the
referring physician at the time of referral. This included
patients referred over a 20 year period; it would therefore
not have been done according to a single standardised set of
current research diagnostic criteria as these have been
modified over this time. However, these changes in defini-
tion are unlikely to have led to misclassifications as we used
only high-level clinical diagnostic categories, and changes
in diagnostic criteria over time have principally focussed on
achieving an earlier or biomarker supported diagnosis.
DemMot was a category we defined to assemble a variety of
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clinical syndromes that comprise a cognitive disorder and
pyramidal or extrapyramidal features, not fitting any of the
other diagnostic categories, eg, Huntington’s disease-like
(all were screened for the Huntington’s disease expansion),
progressive supranuclear palsy, and corticobasal syndrome,
to explore the usefulness of a dementia panel in cryptic
movement disorder cases, which feature dementia as part of
a complex syndrome. Prion disease patients were referred to
the National Prion Clinic for PRNP gene testing based on a
suspicion of inherited prion disease. FTD patients com-
prised the UCL and Cambridge University FTD Cohorts.
CSF results were available to confirm the diagnosis in 78
cases from AD and FTD cohorts, and were consistent with
clinical diagnosis in 91.0%. Neuropathological data were
available for 122 patients (4.5% of all patients) and con-
firmed the clinical diagnosis in 102 (83.6%) of cases. Only
one case with an unexpected mutation went to post-mortem
examination (from our AD cohort with an unexpected
C9orf72 expansion). Neuropathological data confirmed the
expected TDP pathology.
Age at clinical onset (AAO), gender, site of sample
origin, and family history were documented from the clin-
ical notes and referral cards. The strength of a patient’s
family history was quantified with a modified Goldman
score (GS) [8, 9], whereby GS1 corresponds to at least three
affected family members over two generations linked by a
first degree relative; GS2 relates to a patient from a family
with three cases but not fulfilling the criteria for GS1. GS3
relates to one relative with early-onset dementia, or GS3.5
for one relative with late-onset dementia. Cases with a
known negative family history were called GS4, whereas
cases with a censored or unknown family history were
categorised as GS4.5.
Additional to ethnicity documented in our database, we
considered non-white British ethnicity by comparing gen-
otypes at 133 sequenced SNPs from our study participants
to those from individuals from British and continental
outgroup populations genotyped by the 1000 Genomes
study [10]. Although the number of SNPs used was small
for inference of ancestry, we were able to identify
population-specific clusters using principal components
analysis implemented with PLINK [11], and therefore study
participants who were outliers from a British cluster. In this
way we identified 105 individuals (carrying 14 DVs out of
354 in total) with evidence of non-white British ethnicity
(3.2%). DVs identified in these individuals did not bias
overall findings; therefore we included these individuals in
our reports of mutation frequency.
A total of 2974 samples (2517 patients, 457 controls)
were run using the MRC Dementia Gene Panel on an
IonTorrent PGM sequencer (Thermo Fisher Scientific),
which had been previously validated in a blinded in-house
study [7]. Similar gene panels using identical technologies
are also in widespread use in clinically accredited labora-
tories [12]. For quality control and according to the proto-
col, target amplification was assessed via qPCR and
enriched template-postive ion-sphere particles were mea-
sured on a Qubit® 2.0 Fluorometer. For each run, chip
loading and the number of aligned reads were evaluated.
The panel comprised the open reading frame and intron/
exon boundaries of 17 dementia genes: APP, CHMP2B,
CSF1R, FUS, GRN, ITM2B, MAPT, NOTCH3, PRNP,
PSEN1, PSEN2, SERPINI1, SQSTM1, TARDBP, TREM2,
TYROBP and VCP, and was supplemented by repeat-primed
PCR assessment for C9orf72 expansions [13], DNA size
fractionation for the PRNP octapepide repeat insertional
mutation [14], and APOE genotype by minor groove-
binding probe. Data were aligned to the hg37 build in
NextGENe, assessed for an at least 95% 10× target cover-
age and the VCF files exported to GeneticistAssistant (both
Softgenetics) for further analysis. On average, samples had
157,350 mapped sequencing reads, 90% of which were on
target. The average mean depth of coverage was 676 with
an average uniformity of 94.7%; on average, 99.5% of the
target sequence was covered at least 10-fold. In addition to
the average coverage, coverage of the variant (>10×),
zygosity and variant (allele) frequency were assessed for
each variant being analysed in GeneticistAssistant; allele
frequency should be between 0.25 and 0.75 for hetero-
zygous variants, and between 0.8 and 1 for homozygous
variants. If necessary, forward and backward reads (similar
reads in both directions) were evaluated in NextGENe.
C9orf72 expansions and PRNP OPRIs were analysed in
PeakScanner (LifeTechnologies). We screened the dataset
for copy number variants using DeCon version 1.0.1[32],
but could not validate any structural variants. Novel DVs
were confirmed by Sanger-sequencing.
Two hundred and sixty-seven patient samples referred
for testing to the Neurogenetics Laboratory at the NHNN
were sequenced on an Illumina MiSeq or HiSeq platform
using the Neurogenetics Laboratory Dementia Panel, which
included 17 genes: APP, CHMP2B, CSF1R, DNMT1, FUS,
GRN, HTRA1, ITM2B, MAPT, NOTCH3, PRNP, PSEN1,
PSEN2, TARDBP, TREM2, TYROBP and VCP. Both the
Neurogenetics Laboratory and the MRC Prion Unit team
worked together on the validation of the original gene panel
[7], both are laboratories experienced in the quality control,
validation and clinical reporting of gene tests. For this
study, only variants in genes overlapping the MRC
Dementia Gene Panel were included. Library preparation
and enrichment was performed using the Nextera Rapid
Capture Custom Enrichment Kit (Illumina) according to
manufacturer’s protocols. All RefSeq transcripts of the
genes listed were targeted (coding exons ±15 bp flanking
intronic sequences, with the exception of MAPT, which was
sequenced to ±25 bp to cover known intronic splicing
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mutations). A minimum of 99% coverage at 30× and an
average read depth of 500× was consistently obtained in
samples; sequencing regions with coverage lower than 10×
were manually inspected. DVs in these clinically sequenced
samples were confirmed by bi-directional Sanger sequen-
cing. These patient samples were not tested for APOE,
C9orf72 or PRNP insertional mutations.
Seven hundred and fifteen patients who were tested on
the MRC Dementia Gene Panel (AD n= 509, FTD n= 83,
DemMot= 31, Prion= 92, no controls) were also exome
sequenced at Source Bioscience (Nottingham, UK).
Agilent-based exome capture (Agilent, Santa Clara, US)
was followed by paired-end sequencing on the
HiSeq2000 sequencer (Illumina, San Diego, US). Sequen-
cing reads were aligned to GRCh37 using Novoalign fol-
lowed by QC and variant calling in the Genome Analysis
Toolkit, and annotation with ANNOVAR. Mean coverage
across the cohorts was 64×, and 81.5% of targeted
bases were covered >10×. Two DVs were detected in
genes not included in the 17-gene panel (see results).
No other known pathogenic variants were returned by
Ensembl’s Variant Effect Predictor [15] in the exome-
sequencing data.
Variant classification followed the guidelines published
by the American College of Medical Genetics and Geno-
mics and the Association for Molecular Pathology in 2015
[16], for which we introduced clarifications specific to our
disease circumstances and removed criteria unsuited to our
setting (Table 1a and 1b). The algorithm used for classifi-
cation is based on the level of evidence available for each
variant (Table 1a), which is combined for a final classifi-
cation (Table 1b). Intronic variants were assessed using
Human Splicing Finder HSF V3.0 and classified according
to our criteria [17]. Only variants with a population fre-
quency <5% were manually classified. For the Neuroge-
netics Laboratory samples, we did not report likely benign,
benign or synonymous variants.
Statistical analysis for associations, predictors and rela-
tive risks were performed in SPSS (IBM, Version 24) and
included logistic regression, univariate analysis of variance
(ANOVA), and contingency tables. Statistical analyses
were carried out with a pre-defined statistical threshold of
p < 0.01 to account for testing five key independent
hypotheses (see tests labelled Ϯ); subsequent secondary,
exploratory tests were carried out without further correc-
tions for multiple testing.
Penetrance calculations were based on estimates of life-
time risk generated using a Boolean literature search of
PubMed for 'dementia' AND 'epidemiology' from 2008 to
January 2017 to determine incidence and prevalence of
early-onset AD (EOAD) and early-onset FTD (EOFTD).
Subsequent calculations were performed in Microsoft Excel
based on the methodology used in prion disease [18], both
for variants identified in this data set and reportedly
pathogenic variants described in the literature (see Supple-
mentary data for more details).
Results
Baseline characteristics of patients and controls are shown
in Table 2.
Classification of variants
There is no computational or experimental tool to perfectly
classify individual variants by their pathogenicity, the cur-
rent start-of-the-art clinical method is decision making that
considers multiple factors and is adaptable to multiple
potential genes/disease mechanisms (Table 1a and 1b). In
this way we classified 13,152 variants in 3241 individuals
(Fig. 1, Tables 2, 3) and identified 352 DVs (deleterious or
likely deleterious variants) in 341 patients (12.2% of
patients, p= 2.8 × 10−14, OR: 31.8, 95% CI (7.88, 127.94)).
Two additional DVs were seen in two of 457 controls
(0.4%, Fig. 1, Table 3). In addition to these 343 individuals
carrying DVs, 121 possibly deleterious variants were found
in 3.5% of all samples (4.1% patients, 1.3% of controls), in
excess in cases vs. controls (p= 0.005 (Ϯ), OR: 3.06, 95%
CI (1.34, 7.01)), suggesting that two-thirds of variants in
this category might be reclassifiable as DVs if sufficient
data were available; these warrant further research specific
to each case including the potential for segregation in
families. One hundred and forty-three variants that could
not be classified as benign or deleterious, termed uncertain,
were seen in 4.4% samples (4.6% patients, 3.5% controls,
p= 0.39).
Novel variants were defined as variants that had not
previously been reported in the literature nor found in the
Genome Aggregation Database (gnomAD) of exomes and
genomes [19]. Out of the 343 samples with 352 DVs
detected in this data set, 39 (11.3% patients with DVs, χ2
test p= 0.004 (Ϯ)) were novel DVs, Fig. 2; 16 were iden-
tified in GRN, eight in PSEN1, six in MAPT, six in CSF1R
and one each in NOTCH3, PSEN2 and VCP. Because of the
well-known disease mechanism of GRN related to loss of
function, novel variants in this gene were easier to classify
as DVs than those in genes with less well-understood
pathomechanisms.
There have been several reports of concurrent pathogenic
mutations in patients with FTD [20–22]. Eleven patients
were found to carry two DVs (out of chance expectation,
p < 0.001 (Ϯ), Binomial test [23], 3.2% of patients with at
least one DV; one AD patient, seven FTD patients, two
patients with prion disease and one patient with DemMot).
There was a notable excess in FTD, as previously suggested
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by case reports (observed 7, expected 2.7, χ2 test, p=
0.003) [20].
Fourteen DVs were observed in 12 patient samples of
non-UK ancestry; of these, two were C9orf72 expansions
and two cases carried a double DV. None of the DVs found
in samples of non-UK ancestry were observed on gnomAD,
except for the secondary variant of one of the concurrent
mutations, which was described in four South Asian, one
East Asian and three European samples, with a frequency of
0.013%, 0.0058% and 0.0027%, respectively.
Table 1a Evidence used to classify variants according to their pathogenicity level
Evidence level Criteria
Pathogenic Strong 1) Coding amino-acid change previously published as deleterious with evidence of segregation in more than one
pedigree or in multiple unrelated patients with the same phenotype
2) Null variant in a gene where loss of function (LOF) is a known disease mechanism (caveat LOF variants at extreme
3’-end)
3) Variant in a gene associated with an expected very rare pathology (e.g., PRNP mutation and prion pathology)
4) Explained mechanism of pathophysiology of variant using in vitro or in vivo studies
5) Found in a mutational hotspot, i.e., a domain where many other pathogenic mutations are seen, generally with
additionally support from in silico prediction software
Pathogenic Moderate 1) Coding amino-acid change previously and justifiably published as deleterious but without evidence of segregation or
in a single pedigree/patient
2) Novel missense change at an amino-acid residue where a different pathogenic missense change has been seen
3) A very different amino-acid change at the same site or next to one with a less dramatic amino-acid change but
deleterious
4) In a gene, the mechanism of which is understood and the effect of the variant is in keeping with that mechanism
5) Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants
6) Mutation in a gene associated with a rare pathology in a case with a compatible clinical syndrome
7) Intronic variant affecting splicing or protein length
Pathogenic Supporting 1) Variant with a major amino-acid change near or in a functional domain (e.g., active site of an enzyme) but not in a
mutational hotspot
2) Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation,
evolutionary, splicing impact, etc.), caveat: because many in silico algorithms use the same or very similar input for
their predictions, each algorithm should not be counted as an independent criterion
3) Reported in both cases and controls, but more cases than controls (statistically significant in a study)
Pathogenic Risk Factor 1) Previously reported as risk factor, either variant itself or clear established pattern in gene
2) > 1 in 10000 in gnomAD
3) The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in
controls
Benign Independent Allele frequency > 5% on gnomAD, or 1000 genomes project
Benign Strong 1) Allele frequency > 1% on gnomAD
2) Reported benign in multiple pedigrees or with insight into gene/protein mechanism
3) Allele frequency is greater than expected for disorder
4) Lack of segregation in affected members of a family, caveat: phenocopies and penetrance
5) Seen in equal or greater frequencies in controls than cases
Benign Moderate 1) Allele frequency over 0.1% on gnomAD
2) Reported benign in one case or pedigree
3) Genetic mechanism inconsistent with pathological phenotype, or known mutation spectrum
Benign Supporting 1) Missense variant in a gene for which primarily truncating variants are known to cause disease or the mechanism is
very specific and known
2) Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary,
splicing impact, etc.)
3) A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus
sequence
Variants identified in a sample were classified according to the information available about them. This included the type of mutation in question, its
position in the gene and/or protein, its frequency in online population databases, in silico predictions of effects on proteins, and whether it had
previously been reported in families, single cases or controls
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Rare GRN missense variants found in cases and controls
were all classified as possibly pathogenic. Collectively,
compared with controls (1.1%), GRN missense variants
were seen significantly in excess in patients (3.6%, p=
0.004, OR 3.4 (1.4–8.4)) with AD (3.5%, p= 0.006, OR=
3.3) and FTD (3.7%, p= 0.006, OR= 3.4) but not DemMot
(2.5%, p= 0.1, OR= 2.3) or prion disease (2.7%, p= 0.2,
OR= 2.5). Compared with controls (3.7%), heterozygous
TREM2 missense variants were not significantly more
common in dementia syndromes (4.9%; p= 0.3), or in AD
alone (5.9%, p= 0.097; OR= 1.6), albeit consistent with
effect sizes previously reported [24].
715/2984 samples that were analysed with the NGS
gene-panel were also exome sequenced (see Methods),
which allowed discovery of only two additional mutations
classified as DVs, in TBK1 [25] and DNMT1 [26], and no
DVs in other neurology-relevant genes not included in the
panel.
All the analyses reported here were repeated following
exclusion of known family members (n= 73), on the basis
of the proband being identified in the family history of the
second case, with no significant change to any finding.
Phenotypes associated with deleterious or likely
deleterious variants
Neurodegenerative disease syndromes caused by DVs were
found to have broadly similar ages at onset (AAO), inde-
pendent of the gene in which these variants were identified
(Supplementary Figure 1). An overall statistically sig-
nificant difference in AAO by gene (ANOVA, p= 0.003)
was driven by the relatively late clinical onset in GRN and
the relatively early onset of patients with DVs in PSEN1,
MAPT and PRNP. Nevertheless, patients with PRNP DVs
presented with a very wide range of AAO, stretching into
old age (range 22–79 years). DVs discovered in old age
were not restricted to PRNP, and included APP, PSEN1,
C9orf72, GRN, MAPT, CHMP2B, CSF1R, TYROBP and
VCP.
DVs were often discovered in patients with clinical
syndromes that would not normally prompt a request for
sequencing of the implicated gene. In 58 patient samples,
DVs were identified in genes that would not normally be
screened in the clinical syndrome (16.9% of all patients
with DVs, p= 0.013 (Ϯ)), Fig. 3. In patients diagnosed with
AD we found three C9orf72 expansions, nine DVs in
MAPT, five in CSF1R, two in GRN, three in PRNP and one
each in SQSTM1, TARDBP and VCP, as well as a homo-
zygous TREM2 DV normally associated with Nasu-Hakola
disease. For FTD patients, five were seen in VCP, three
variants each were seen in CSF1R and PSEN1, two in
PRNP and SQSTM1, and one each in NOTCH3 and
CHMP2B. Two DVs in PSEN1 and one each in GRN and
VCP were identified in patients referred with suspected
prion disease, the latter as part of a concurrent mutation
with a PRNP DV. In DemMot, four DVs were identified in
PSEN1, three variants in MAPT, as well as one variant each
in ITM2B, PRNP, GRN and PSEN2 were found.
Table 1b Criteria for variant
classification
Pathogenicity Algorithm
Deleterious Found in patient(s) and not controls OR in significant excess in patients AND seen
on gnomAD at < 1 in 50,000;
AND Pathogenic Strong evidence 1) OR 2),
PLUS one additional Pathogenic Strong or two Pathogenic Moderate or one
Pathogenic Moderate and one Pathogenic Supporting criterion
Likely deleterious The prevalence of the variant in affected individuals is significantly increased
compared with the prevalence in controls, or only seen on gnomAD at < 1 in 10,000;
AND Pathogenic Moderate evidence 1) OR 2) OR 3)
AND one additional Pathogenic Strong or Moderate or Supporting criteria
Possibly deleterious Found on gnomAD at < 1 in 5000 and at least one Supporting criterion
Uncertain Insufficient or conflicting evidence
Missense mutation not nearby other missense mutations thought to be pathogenic
Likely benign One Benign Strong criteria OR one Benign Moderate AND one Benign Supporting
criteria OR two Benign Supporting criteria
Benign Benign Independent OR one Benign Strong evidence criterion AND two further
Benign Moderate or Benign Supporting criteria
Risk factor Previously reported as risk factor, either variant itself or clear established pattern in
gene,
AND > 1 in 10,000 in gnomAD;
AND the prevalence of the variant in affected individuals is significantly increased
compared with the prevalence in controls
The evidence available about each variant was combined to determine its likely effect and likelihood of
causing disease
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Predictors of deleterious or likely deleterious
variants (Ϯ)
Coverage, sex, ethnicity, healthcare setting, and pro-
spective/retrospective recruitment did not influence the
likelihood of a DV (p= 0.97, p= 0.33, 0.68, 0.61 and p=
0.53, respectively, logistic regression); we therefore com-
bined genders, ethnicities, sample coverage, sampling
method and sample referral sites in further analyses. Com-
pared with controls, AD (logistic regression, p= 0.006;
Odds ratio (OR): 7.46, 95% confidence interval (CI) (1.77,
31.49)), FTD (p= 2.0 × 10−6; OR: 33.58, 95% CI (7.95,
141.81)), Prion patients (p= 2.24 × 10−9; OR: 92.54, 95%
CI (20.98, 408.184)) and DemMot patients (p= 0.042;
Odds ratio: 4.7, 95% CI (1.06, 20.87)) were significantly
more likely to carry a DV in order of declining frequency
Prion > FTD >AD >DemMot (Table 3).
AAO was a very strong predictor of finding a DV (p=
3.8 × 10−9, logistic regression, Fig. 4). Risk was high from
early adulthood through to middle age and steadily declined
into old age without clear change in risk at the traditional
boundary of early and late-onset disease, age 65. Family
history was also highly predictive of a DV (p= 4.6 × 10−38,
logistic regression, Fig. 5). This association was also strong
in late-onset dementia, in which circumstance GS remained
highly predictive of identifying a DV (p= 2.3 × 10−4,
logistic regression), but age at onset no longer had a sig-
nificant effect (p= 0.452). The combined effects of AAO,
clinical syndrome and family history were considered in
recommendations for use of dementia gene panels (Fig. 6).
In the AD cohort, unsurprisingly, ApoE genotypes 3/4
and 4/4 were significantly enriched (p= 3.0 × 10−4 and p=
0.001, χ2 test, respectively); for FTD patients, the ApoE
genotype 4/4 was also significantly enriched (p= 6.7 ×
10−4, χ2 test). In total, 75% of GS1 AD patients and 71% of
GS1 FTD patients (all ages) had either a DV or one ApoE4
genotype.
Penetrance calculations in EOAD and EOFTD
Minikel et al. [18] evaluated the penetrance of PRNP var-
iants showing that some of those previously suspected to be
DVs were neither highly penetrant nor benign. We therefore
attempted to discover similarly partially penetrant DVs
using the gene panel. The method used by Minikel requires
an estimate of lifetime risk of disease and population fre-
quency of a variant. We estimated lifetime risk of EOAD (1
in 3194) and EOFTD (1 in 3276) (see Supplementary data).
We assessed the likely penetrance of reported DVs in APP,
PSEN1 and PSEN2 for EOAD and GRN, MAPT and VCP
for EOFTD both in the literature and novel variants dis-
covered in this study. Assuming a proportion of autosomal
dominant genetic cases of 10% for EOAD [27] and 20% for
Fig. 2 Genes in which novel DVs were found. Eleven percent of DVs
were not previously described in the literature (n= 39). Known
mutations were found in PRNP (24.6%), C9orf72 (19.2%), MAPT
(15.8%), GRN (9.9%), PSEN1 (9.6%), APP (3.4%), CSF1R (2.0%),
VCP (1.7%), SQSTM1 (0.9%), TARDBP (0.6%) and CHMP2B,
ITM2B, NOTCH3, PSEN2 and TREM2 (0.3% each)
Fig. 1 Frequency of variant pathogenicity classes in the data set. This
figure shows the frequency of the various variant pathogenicity classes
in the total data set broken down by individual phenotypes
Fig. 3 Chart illustrating the association between clinical syndrome and
gene implicated. Numbers on the left refer to patients with clinical
syndromes, numbers of the right refer to DVs in implicated genes
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EOFTD [28], our calculations led to an expectation of 26
DVs among the 141,352 individuals on the gnomAD online
database [19], but instead 182 variants were counted. For
EOFTD, we would have expected to see 51 DVs in gno-
mAD, whereas we found 36 variant counts . The prevalence
of AD deleterious variants in the literature [29] therefore
vastly exceeds our estimates based on the prevalence of
genetic early-onset dementia, in the assumption of high
penetrance and high ascertainment. We therefore went on to
test whether evidence from our study and data publicly
available would revise classification of variants and clarify
those deemed 'unclear'.
In the molgen database [29] and on the mutation data-
base of Alzforum, 302 variants in APP, PSEN1 and PSEN2
and 153 variants in GRN, MAPT and VCP were listed as
deleterious and a further 21 variants in APP, PSEN1 and
PSEN2 and 64 variants in GRN, MAPT and VCP were
reported as having unclear pathogenicity (Supplementary
data). Many of the reported DVs are not observed at all, or
found at very low frequencies resulting in estimates of
penetrance with very wide confidence intervals, however,
71 purported DVs were detected in gnomAD, calling into
question the extent of their pathogenicity and penetrance
(Supplementary Tables 1S–3S). Based on their relative
frequency in cases and the general population, most of the
variants classified as DVs in our data set appear to be highly
penetrant pathogenic mutations, with three exceptions. APP
Ala713Thr was observed once in our AD cohort and despite
being reported as pathogenic in the literature, its population
frequency suggests low penetrance for EOAD of 0.4%
(95% CI 0.1–2.4%), MAPT Gly389Arg (observed twice in
our data set) was estimated to have 10.2% penetrance (95%
CI 1.6–63.5%) and PSEN1 Ile227Val (observed once in our
data set) was estimated to have 2.9% penetrance (95% CI
0.3–26.9%) (See Tables 1S–3S for more details).
Discussion
Numerous Mendelian genetic causes of dementia have been
discovered over the last 28 years, but the translation of this
knowledge into routine clinical practice has been limited
[30]. Until recently, only a small number of tests were
clinically available. Here, we try to bridge this gap by
providing data to support gene-panel diagnostics in
dementia through analysis of a series of patients enriched
for those likely to be carrying deleterious mutations, and
large enough to inform clinical practice. The identification
of clinically relevant variants in our series was high in all
groups aside from the elderly with a negative family history
and those with dementia and motor symptoms that may not
be caused by variants in typical dementia genes. We also
discovered a high rate of novel variants and known variants
in genes that even an experienced clinician would probably
not have selected for single gene tests based on the clinical
syndrome. Our results therefore justify broader clinical
testing than hitherto customary. We identified clinical syn-
drome, age and the strength of the family history as pre-
dictive factors that should help guide counselling and
decisions about referral for testing. Although many variants
of uncertain significance remain and additional evidence is
needed, these data, in tandem with large-scale population
data, provide some of the evidence base needed for
improved information and guidance in genetic testing.
Clinical syndrome was a strong predictor of the chance
of detecting a mutation and the gene, but in markedly
Fig. 4 Proportion of patients with a deleterious or likely deleterious
variant per age group (%). The distribution is skewed towards the
younger ages of onset, but we discovered many patients with DVs
associated with elderly ages of onset, particularly in the presence of a
family history
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different ways. Ninety-four percent of suspected prion dis-
ease cases with DVs were linked to a single gene, PRNP;
93.5% of FTD patients with DVs were linked to three
major, and two additional genes associated with FTD syn-
dromes (C9orf72, GRN, MAPT, SQSTM1, VCP); however,
in only 63% of clinically diagnosed AD patients were the
DVs in genes linked to AD pathologies (APP, PSEN1 or
PSEN2). DVs in patients with a dementia-motor syndrome
were uncommon and heterogeneous in their associations.
These findings have implications for clinical practice: it
would be reasonable to refer suspected prion disease
patients for testing of PRNP alone. For FTD and AD syn-
dromes, the dementia gene-panel approach seems sensible
owing to the diversity of genes involved and phenotypic
heterogeneity. Dementia-motor syndromes are more chal-
lenging however; a low rate of DV discovery either implies
that disease relevant variants are not covered by our panel.
This would not be surprising as we did not screen genes
associated with familial Parkinson’s disease or the expan-
sion disorders linked to HD phenocopy syndromes other
than C9orf72; alternatively, these patients may harbour a
low rate of single gene disorders. Despite the prominent role
dementia plays in these patients’ clinical syndromes, a panel
covering typical dementia genes only is of limited use in
this cohort; more research is needed to resolve this question.
The low additional rate of mutation detection by research
exome sequencing argues in favour of panel-based testing,
which should be more cost-effective and avoids issues
related to incidental detection of clinically relevant
variants. We have not generated data to allow a rigorous
comparison of alternative gene-panel technologies or com-
position, augmented exomes, genomes or other diagnostic
approaches.
Age at onset was also a strong predictor of finding a DV.
However, this was not an absolute rule, with the rate of DV
detection being 13.5% in those with AAO < 65 and 7.2% in
those with AAO > 65, which was a surprising finding per-
haps related to the selection bias inherent in our referral
based sample. Family history remained an important pre-
dictor in all age groups. Our findings therefore encourage
the use of gene panels in late-onset dementia where there is
evidence of a family history measured using a tool like the
Goldman score. Only 6 DVs in 233 patients (2.6%) were
found in late-onset dementia with a negative family history
(GS4), three in PRNP, two C9orf72 expansions and one in
GRN, so if the family history is negative in late-onset
dementia it seems reasonable not to consider gene-panel
testing, as would be normal practice at the moment. We
recommend dementia gene-panel diagnostics are considered
in all early-onset patients, and late-onset patients with evi-
dence of a genetic disorder in the family history (GS1, 2 or
3) [11]. We have made suggestions based on these findings
(see flowchart Fig. 6); beyond the report of our experience,
opinions will vary among physicians and patients about
what level of risk justifies gene-panel testing. Indeed, some
clinicians/patients/families may feel that even low risks
< 5% of a DV would justify testing.
As there are no proven disease-modifying treatments yet
available, some may question why an effort should be made
to identify Mendelian causes of dementia [31]. However,
many arguments can be brought in favour of identifying
patients who carry pathogenic variants. These include the
provision of a precise diagnosis, removing the need for
further potentially invasive diagnostic tests and providing
information about prognosis. It also opens up access to
patient support from a community with a shared molecular
pathology, who often lend strong lobbying and practical
support to research and care in their condition. Genetic
diagnosis allows for precision medicine in current and
forthcoming clinical trials, for which there are several active
examples. A positive genetic test in a relative also provides
the opportunity for siblings or descendants to make an
informed decision about testing. Our data should provide
information to help doctors and genetic counsellors discuss
risks with patients and their families to make informed joint
decisions about clinical gene testing.
Our sampling strategy was to be representative of cases
being considered for genetic testing by referring physicians.
Bias in referrals owing to selection will have influenced the
prevalence of DVs seen in this study vs. a population-based
study or unselected dementia patients; however, a true
population study would have to be very large indeed to
detect a similar number of DVs. Although acknowledging
Fig. 5 Family history is a strong predictor for the identification of a
deleterious or likely deleterious variant Stratifying cases by Goldman
Score reveals its strong predictive value in identifying cases with a
DV; however, deleterious or likely deleterious variants are found in
clinically relevant proportions of cases with no (GS4) or a censored
(GS4.5) family history
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selection bias as a limitation, we found no difference in
rates of DV detection in prospectively referred cases, or
those referred for a UK NHS clinical accredited service,
implying that our findings are generalisable to cognitive
clinic cases that physicians might consider referring. We
were also limited by a selection of dementia genes and
blinded validation studies that were done in 2014. The only
major Mendelian disease gene to be discovered in the
study’s relevant dementia syndromes is TBK1 associated
with FTD (found in a single patient by exome sequencing).
More work is needed to improve information in the lit-
erature and databases about the pathogenicity and pene-
trance of variants. An excess of potential DVs is seen in
population data, incompatible with the observed pre-
valences of early-onset dementias. Both for EOAD and
EOFTD, variants have been reported as potentially dele-
terious, which are most likely either benign or low pene-
trance. Large-scale studies harnessing the power of NGS are
vital tools to ensure clinical diagnosis, testing and feedback
are as accurate as possible. Improved sharing of patient
genetic data, the availability of large-scale population data,
improved in silico and in vitro modelling, particularly for
less commonly involved genes and dementia syndromes
should help improve the accuracy of classification [19]. We
encourage the development of guidelines and funding to
support sharing of clinical and genetic data in databases to
further improve the accuracy of classification.
Increased genetic testing of a wide range of patients with
diverse dementia syndromes promises opportunities for the
patient, clinician and research, but also implies a burden for
Clinical Genetics services. Similarly, predictive genetic
testing in blood relatives ensuing from diagnosis in a pro-
band, can have a considerable psychological impacts and
the involvement of at-risk individuals from families in
decisions about gene diagnostics is crucial.
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